These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18764722)

  • 21. Targeted therapies in diabetic nephropathy: an update.
    Gupta A; Gupta P; Biyani M
    J Nephrol; 2011; 24(6):686-95. PubMed ID: 22058027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy.
    Kelly DJ; Buck D; Cox AJ; Zhang Y; Gilbert RE
    Am J Physiol Renal Physiol; 2007 Aug; 293(2):F565-74. PubMed ID: 17522264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel insights in the treatment of diabetic nephropathy.
    Schrijvers BF; De Vriese AS
    Acta Clin Belg; 2007; 62(5):278-90. PubMed ID: 18229460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
    Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
    Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced glycation end products and diabetic nephropathy.
    Thomas MC; Forbes JM; Cooper ME
    Am J Ther; 2005; 12(6):562-72. PubMed ID: 16280650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update concept of the dual blocking of the renin-angiotensin-aldosteron system. A new therapeutic option?
    León Jiménez D; Castilla Guerra L; López Chozas JM; Miramontes González JP
    Med Clin (Barc); 2018 Jan; 150(1):33-38. PubMed ID: 28668172
    [No Abstract]   [Full Text] [Related]  

  • 31. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New pharmacological treatments for improving renal outcomes in diabetes.
    Declèves AE; Sharma K
    Nat Rev Nephrol; 2010 Jun; 6(6):371-80. PubMed ID: 20440278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AGE, RAGE, and ROS in diabetic nephropathy.
    Tan AL; Forbes JM; Cooper ME
    Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
    Sourris KC; Yao H; Jerums G; Cooper ME; Ekinci EI; Coughlan MT
    Curr Drug Targets; 2016; 17(11):1252-64. PubMed ID: 26201485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists.
    Hsueh WA
    Curr Opin Pharmacol; 2002 Apr; 2(2):182-8. PubMed ID: 11950631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
    Fronczyk A; Majkowska L
    Przegl Lek; 2007; 64(2):81-5. PubMed ID: 17892038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New findings with RAS inhibitors in diabetic nephropathy].
    Ito S
    Nihon Jinzo Gakkai Shi; 2007; 49(5):485-90. PubMed ID: 17695809
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.